Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Extemporaneous compounding is a means to tailor a medication to an individual patient's needs and may be required when no commercial product exists to meet that need. Compounded products range from buffered lidocaine to topical creams and ointments. Recent heightened regulations have made compounding more challenging for dermatologists and prompted this review of regulations, liability, and safety related to compounding. With this information, providers may minimize liability and maximize safety while caring for their patients.Le texte complet de cet article est disponible en PDF.
Key words : botulinum toxin, compounding, cost, economics, financial, formulation, levigation, lidocaine, regulations, regulatory requirements, safety
Abbreviations used : FDA, USP
| Funding sources: None.
| Conflicts of interest: None disclosed.